Our startup addresses the critical issue of avian pathogenic E. coli (APEC) infections in poultry, a leading cause of disease and economic losses in the industry. Current reliance on antibiotics to combat APEC raises concerns about resistance and animal welfare. We aim to solve this by developing a probiotic live vaccine that offers a sustainable solution to prevent and control APEC infections, reducing the need for antibiotics and improving overall poultry health, productivity, and food safety.
Our founding team has a proven track record in microbiology and immunology, focused on developing an innovative vaccine solution to combat APEC in poultry. This addresses the global poultry health market, providing an alternative to antibiotics while improving welfare and productivity.
